Incidence of new primary melanomas after diagnosis of stage III and IV melanoma

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 816-823

  Zimmer, Lisa ^a   Haydu, Lauren E ^b,e   Menzies, Alexander M ^b,c   Scolyer, Richard A ^b,c,d   Kefford, Richard F ^b,c,g   Thompson, John F ^b,d,e,f   Schadendorf, Dirk ^a   Long, Georgina V ^b,c,g  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Mater Hospital   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MELANOMA; MIDDLE AGED; NEW PRIMARY MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; ADOLESCENT; AGED; AUSTRALIA; CANCER STAGING; CHILD; INCIDENCE; PATHOLOGY; RISK FACTOR; SECOND CANCER; SEX DIFFERENCE; SKIN TUMOR; TIME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CHILD; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; SEX FACTORS; SKIN NEOPLASMS; TIME FACTORS; YOUNG ADULT;

EID: 84897971918     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.5572     Document Type: Article

References (36)

1. International Agency for Research on Cancer: Cancer incidence in five continents. Vol IX. CANCERMondial. Lyon, France, IARC Cancer-Base, No 160, 2007; (France) Vol IX. http://www.dep.iarc.fr/
2. van der Leest RJ, Liu L, Coebergh JW, et al: Risk of second primary in situ and invasive melanoma in Dutch population-based cohort: 1989-2008. Br J Dermatol 167:1321-1330, 2012
3. Karahalios E, English D, Thursfield V, et al: Second primary cancers in Victoria, Victorian Cancer Registry 1982-2005. http://www.cancervic.org.au/ about-our-research/registry-statistics/cancer-in-victoria/second-primary- cancers-victoria
4. Levi F, Randimbison L, Te VC, et al: High constant incidence rates of second cutaneous melanomas. Int J Cancer 117:877-879, 2005 (Pubitemid 41598843)
5. Bradford PT, Freedman DM, Goldstein AM, et al: Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146:265-272, 2010
6. Hwa C, Price LS, Belitskaya-Levy I, et al: Single versus multiple primary melanomas: Old questions and new answers. Cancer 118:4184-4192, 2012
7. Ferrone CR, Ben Porat L, Panageas KS, et al: Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294:1647-1654, 2005 (Pubitemid 41407357)
8. McCaul KA, Fritschi L, Baade P, et al: The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control 19:451-458, 2008
9. Goggins WB, Tsao H: A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 97:639-643, 2003 (Pubitemid 36125840)
10. Lee CC, Faries MB, Wanek LA, et al: Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol 26:535-541, 2008 (Pubitemid 351264345)
11. Balch CM, Gershenwald JE, Soong SJ, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
12. Atkins M, Long G, Warneke C, et al: Unraveling the prognostic heterogeneity in patients with advanced melanoma between Australia (OZ) and the United States (US): Preliminary report of the PHAMOUS study. J Clin Oncol 28, 2010 (suppl 15S; abstr 8516)
13. Lee CC, Faries MB, Wanek LA, et al: Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol 27:3489-3495, 2009
14. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
15. Long GV, Menzies AM, Nagrial AM, et al: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239-1246, 2011
16. Ribas A, Flaherty KT: BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8:426-433, 2011
17. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
18. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
19. Hauschild A, Grob JJ, Demidov LV, et al: An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). J Clin Oncol 31, 2013 (suppl; abstr 9013)
20. Chapman PB, Hauschild A, Robert C, et al: Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 30, 2012 (suppl; abstr 8502)
21. Dalle S, Poulalhon N, Thomas L: Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 365:1448-1449, 2011
22. Zimmer L, Hillen U, Livingstone E, et al: Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-2383, 2012
23. Haenssle HA, Kraus SL, Brehmer F, et al: Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: Importance of sequential dermoscopy. Arch Dermatol 148:1183-1185, 2012
24. Murali R, Brown PT, Kefford RF, et al: Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma. Cancer 118:4519-4529, 2012
25. Sherif BN: A comparison of Kaplan-Meier and cumulative incidence estimate in the presence or absence of competing risks in breast cancer data. Submitted to the Graduate Faculty of Graduate School of Public Health in partial fulfillment of the requirements for the degree of Master of Science, University of Pittsburgh, Pittsburgh, PA, 2007. http://d-scholarship.pitt.edu/9986/1/ BintuSherif-thesis%5B1%5D.pdf
26. DiFronzo LA, Wanek LA, Elashoff R, et al: Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol 6:705-711, 1999
27. Orlow I, Tommasi DV, Bloom B, et al: Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol 129:1972-1982, 2009
28. Berwick M, Orlow I, Hummer AJ, et al: The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: An international population-based study. Cancer Epidemiol Biomarkers Prev 15:1520-1525, 2006 (Pubitemid 44299326)
29. Poulikakos PI, Zhang C, Bollag G, et al: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-430, 2010
30. Hatzivassiliou G, Song K, Yen I, et al: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-435, 2010
31. Palmieri G, Sini M, De Giorgi V, et al: Assessment of germ-line and somatic alterations in main candidate genes among patients with multiple primary melanoma. J Clin Oncol 30, 2012 (suppl; abstr 8581)
32. Chapman P, Metz D, Sepulveda A, et al: Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res 25:847, 2012 (abstr)
33. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-2321, 2012
34. Robert C, Thomas L, Bondarenko I, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
35. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
36. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012